bevacizumab for the treatment of patients with ovarian cancer exhibiting poor chemosensitivity
Published 2 years ago • 834 plays • Length 0:47Download video MP4
Download video MP3
Similar videos
-
3:47
gog-0218: which patients with ovarian cancer experience highest benefit from 1l bevacizumab?
-
3:11
the avanova study: niraparib and bevacizumab for ovarian cancer
-
1:19
real-world use of bevacizumab in patients with breast cancer
-
0:34
improving immunotherapy for the treatment of patients with ovarian cancer
-
2:50
aurelia: phase 3 trial of bevacizumab combined with chemotherapy for ovarian cancer
-
2:27
the paola-1 study: olaparib and bevacizumab for ovarian cancer
-
0:45
results for combination bevacizumab plus mirvetuximab soravtansine in ovarian cancer
-
2:10
laparoscopic paraovarian cystectomy
-
1:05
areas of unmet need for patients with ovarian cancer
-
0:52
dr. mirza on safety profile of niraparib/bevacizumab in recurrent ovarian cancer
-
1:47
dr. monk on the utility of bevacizumab for cervical cancer
-
24:34
top advances in ovarian cancer therapy
-
57:43
professor gordon jayson: treating ovarian cancer with anti-angiogenic agents
-
7:32
bevacizumab for recurrent ovarian cancer
-
2:11
approaching frontline therapy options for ovarian cancer
-
3:28
implications of paola-1 in advanced ovarian cancer
-
57:47
the effectiveness of bevacizumab (avastin) and related trials
-
1:59
ovarian cancer subtypes may predict response to bevacizumab
-
1:12
dr. herzog on the optimal use of bevacizumab in patients with ovarian cancer